所有产品
  • 抗体
  • 试剂盒
  • 多肽
  • 蛋白
  • 生化试剂
  • 组织芯片
EN
cAMP/ cGMP/ Protein A/ β-Actin/ BSA/ Ddx4/ APOE/ TAU pT181/ TAU pT217/ Tau 1-441/ Aβ1-40/ Aβ1-42/ α-Syn/ GFAP/ IL/ CD/ 标记试剂盒/ GFP/ Flag/ 多肽合成服务/ /
抗体药类似物
当前位置：首页 > 产品中心 > 抗体 > 抗体药类似物
产品中心
Product Center
Research Grade Polatuzumab
All
SEC-HPLC
Bioactivity
SDS-PAGE
  • Catalog： TD-HW431016
  • Clonality： Monoclonal
  • Application： ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Synonyms： ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumabvedotin-piiq, 1313206-42-6
  • 规格：
    询价
  • 价格：
    ¥100ug
定制服务咨询
详细相关信息
FAQ
实验方案
参考文献
  • Catalog No.
    TD-HW431016
  • Description
    Polatuzumab(TD-HW431016) is a research-grade recombinant antibody targetingCD79B. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
  • Species reactivity
    Human
  • Applications
    ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Host species
    Humanized
  • Isotype
    IgG1-kappa
  • Clonality
    Monoclonal
  • Target
    B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b
  • Endotoxin level
    Please contact the lab for this information.
  • Purity
    >95% purity as determined by SDS-PAGE.
  • Purification
    Protein A/G purified from cell culture supernatant.
  • Accession
    P40259
  • Form
    Liquid
  • Storage buffer
    0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
  • Stability and Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
  • Alternate Names
    ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumabvedotin-piiq, 1313206-42-6
  • Background
    Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients.
  • Caption
    SEC-HPLC detection for Research Grade Polatuzumab.　　|　Detects Human CD79β/CD79B in indirect ELISAs.　　|　SDS-PAGE for Research Grade Polatuzumab.
  • Note
    For research use only. Not suitable for clinical or therapeutic use.